ArticleHaematologica2026

Real-world safety and tolerability of rapid infusion obinutuzumab in chronic lymphocytic leukemia, small lymphocytic lymphoma and non-Hodgkin lymphoma: a provincial review.

Harshal Senthil et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.